Clinuvel Pharmaceuticals Limited (CLVLF)
USD 6.95
(-4.79%)
USD 6.95
(-4.79%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 30.09 Million AUD | 18.33% |
| 2023 | 25.42 Million AUD | 27.73% |
| 2022 | 19.9 Million AUD | 32.45% |
| 2021 | 15.03 Million AUD | 30.19% |
| 2020 | 11.54 Million AUD | 49.94% |
| 2019 | 7.69 Million AUD | 4.72% |
| 2018 | 7.35 Million AUD | 23.23% |
| 2017 | 5.96 Million AUD | -10.42% |
| 2016 | 6.66 Million AUD | -42.42% |
| 2015 | 11.56 Million AUD | 119.41% |
| 2014 | 5.27 Million AUD | -46.38% |
| 2013 | 9.83 Million AUD | -10.84% |
| 2012 | 11.02 Million AUD | -19.92% |
| 2011 | 13.77 Million AUD | -15.91% |
| 2010 | 16.37 Million AUD | -9.97% |
| 2009 | 18.19 Million AUD | -3.49% |
| 2008 | 18.84 Million AUD | 63.09% |
| 2007 | 11.55 Million AUD | -0.85% |
| 2006 | 11.65 Million AUD | -6.4% |
| 2005 | 12.45 Million AUD | 42.58% |
| 2004 | 8.73 Million AUD | 78.0% |
| 2003 | 4.9 Million AUD | 18.34% |
| 2002 | 4.14 Million AUD | 11419.44% |
| 2001 | 36 Thousand AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 8.77 Million AUD | 0.0% |
| 2024 FY | 30.09 Million AUD | 18.33% |
| 2024 Q1 | 8.59 Million AUD | 54.62% |
| 2024 Q2 | 5.58 Million AUD | -35.01% |
| 2023 Q2 | 7.94 Million AUD | 37.33% |
| 2023 FY | 25.42 Million AUD | 27.73% |
| 2023 Q1 | 5.78 Million AUD | -16.54% |
| 2023 Q3 | 7.18 Million AUD | -9.62% |
| 2023 Q4 | 5.56 Million AUD | -22.56% |
| 2022 Q1 | 5.06 Million AUD | -56.77% |
| 2022 FY | 19.9 Million AUD | 32.45% |
| 2022 Q4 | 6.93 Million AUD | 36.11% |
| 2022 Q3 | 5.09 Million AUD | -23.18% |
| 2022 Q2 | 6.62 Million AUD | 30.83% |
| 2021 Q2 | 9.53 Million AUD | 151.34% |
| 2021 Q4 | 11.72 Million AUD | 154.16% |
| 2021 Q3 | 4.61 Million AUD | -51.66% |
| 2021 Q1 | 3.79 Million AUD | -68.2% |
| 2021 FY | 15.03 Million AUD | 30.19% |
| 2020 Q4 | 11.93 Million AUD | 776.1% |
| 2020 FY | 11.54 Million AUD | 49.94% |
| 2020 Q1 | 4.75 Million AUD | -45.19% |
| 2020 Q2 | 8.06 Million AUD | 69.59% |
| 2020 Q3 | 1.36 Million AUD | -83.1% |
| 2019 Q2 | 2.49 Million AUD | -0.0% |
| 2019 Q3 | 4.01 Million AUD | 61.04% |
| 2019 FY | 7.69 Million AUD | 4.72% |
| 2019 Q1 | 2.49 Million AUD | -20.36% |
| 2019 Q4 | 8.67 Million AUD | 115.8% |
| 2018 Q3 | 3.13 Million AUD | 12.57% |
| 2018 Q4 | 3.13 Million AUD | 0.0% |
| 2018 Q2 | 2.78 Million AUD | 0.0% |
| 2018 FY | 7.35 Million AUD | 23.23% |
| 2018 Q1 | 2.78 Million AUD | 13.73% |
| 2017 Q2 | 2.2 Million AUD | 0.0% |
| 2017 Q1 | 2.2 Million AUD | 30.52% |
| 2017 Q4 | 2.44 Million AUD | 0.0% |
| 2017 FY | 5.96 Million AUD | -10.42% |
| 2017 Q3 | 2.44 Million AUD | 11.15% |
| 2016 Q1 | 2.43 Million AUD | 1457.67% |
| 2016 FY | 6.66 Million AUD | -42.42% |
| 2016 Q4 | 1.68 Million AUD | 0.0% |
| 2016 Q3 | 1.68 Million AUD | -30.73% |
| 2016 Q2 | 2.43 Million AUD | -0.0% |
| 2015 Q2 | 4.24 Million AUD | -0.0% |
| 2015 Q3 | 156.36 Thousand AUD | -96.31% |
| 2015 FY | 11.56 Million AUD | 119.41% |
| 2015 Q4 | 156.36 Thousand AUD | 0.0% |
| 2015 Q1 | 4.24 Million AUD | 113.64% |
| 2014 FY | 5.27 Million AUD | -46.38% |
| 2014 Q4 | 1.98 Million AUD | 0.0% |
| 2014 Q1 | 2.08 Million AUD | 2.18% |
| 2014 Q2 | 2.08 Million AUD | -0.0% |
| 2014 Q3 | 1.98 Million AUD | -4.79% |
| 2013 FY | 9.83 Million AUD | -10.84% |
| 2013 Q3 | 2.04 Million AUD | 0.0% |
| 2013 Q4 | 2.04 Million AUD | 0.0% |
| 2012 FY | 11.02 Million AUD | -19.92% |
| 2011 FY | 13.77 Million AUD | -15.91% |
| 2010 FY | 16.37 Million AUD | -9.97% |
| 2009 FY | 18.19 Million AUD | -3.49% |
| 2008 FY | 18.84 Million AUD | 63.09% |
| 2007 FY | 11.55 Million AUD | -0.85% |
| 2006 FY | 11.65 Million AUD | -6.4% |
| 2005 FY | 12.45 Million AUD | 42.58% |
| 2004 FY | 8.73 Million AUD | 78.0% |
| 2003 FY | 4.9 Million AUD | 18.34% |
| 2002 FY | 4.14 Million AUD | 11419.44% |
| 2001 FY | 36 Thousand AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -724.253% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2143.015% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1045.226% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -1.821% |
| GB Sciences, Inc. | 1.42 Million USD | -2018.329% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -783.737% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -13572.907% |
| Skye Bioscience, Inc. | 13.54 Million USD | -122.114% |
| Zenith Capital Corp. | 8.94 Million USD | -236.476% |
| Agentix Corp. | 1.37 Million USD | -2093.616% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -496.803% |
| Biomind Labs Inc. | 994.18 Thousand USD | -2926.716% |
| ContraFect Corporation | 56.88 Million USD | 47.106% |
| CSL Limited | 3.44 Billion USD | 99.128% |
| CytoDyn Inc. | 18.05 Million USD | -66.636% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1514.007% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7624.252% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 47.613% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7142.499% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1903.534% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3158.336% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 19.231% |
| SQZ Biotechnologies Company | 85.61 Million USD | 64.855% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1368.784% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 65.327% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -931.846% |
| Mesoblast Limited | 5.9 Million USD | -409.845% |
| Marizyme, Inc. | 19.23 Million USD | -56.4% |
| Genus plc | 147.7 Million USD | 79.627% |
| Pharming Group N.V. | 225.49 Million USD | 86.655% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -260.847% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1934.896% |
| IMV Inc. | 37.7 Million USD | 20.202% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -978.395% |
| MultiCell Technologies, Inc. | 567.42 USD | -5303037.182% |
| ONE Bio Corp. | 6.44 Million USD | -366.97% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 64.988% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -21.752% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1610.032% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -347.916% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 120464.244% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -87.949% |
| Alpha Cognition Inc. | 9.7 Million USD | -210.038% |
| Enzolytics Inc. | 2.17 Million USD | -1280.636% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.038% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2782.286% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1151.222% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.354% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -511.866% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -11397.162% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1125.547% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -17444.887% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1466.504% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -242.753% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -582.543% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -703.195% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1425.89% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5556.619% |
| Q BioMed Inc. | 3.43 Million USD | -775.598% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -176.903% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 69.706% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -30.974% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1539.755% |
| HST Global, Inc. | 140.9 Thousand USD | -21255.263% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2153.285% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2574.975% |
| Halberd Corporation | 74.84 Thousand USD | -40106.116% |
| Resverlogix Corp. | 12.71 Million USD | -136.714% |
| Cell Source, Inc. | 4.32 Million USD | -595.691% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1805.275% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -311.628% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -172628.667% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -1119.861% |
| Kadimastem Ltd | 2.41 Million USD | -1148.534% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -609.96% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -16480.467% |
| LadRx Corporation | 3.81 Million USD | -689.421% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3158.336% |
| Affymax, Inc. | 39.38 Million USD | 23.6% |
| Itoco Inc. | 919.14 Thousand USD | -3173.817% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2589.103% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5326.252% |
| International Stem Cell Corporation | 5.27 Million USD | -470.88% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -687.694% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -119456.045% |
| Qrons Inc. | 643.67 Thousand USD | -4574.87% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2019.399% |
| SYBLEU INC | 160.87 Thousand USD | -18604.506% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1249.448% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4431.786% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1556.705% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -57061.698% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -147818.503% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 17.027% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1759.769% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -3989.376% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -867.247% |
| Neutra Corp. | 243.82 Thousand USD | -12241.456% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -72.372% |
| PureTech Health plc | 144.59 Million USD | 79.19% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -46.858% |
| IXICO plc | 4.7 Million USD | -539.283% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -242.06% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 74.445% |
| CSL Limited | 3.89 Billion USD | 99.227% |
| Cellectis S.A. | 97.32 Million USD | 69.08% |